Mevastatin
Product Code:
CDX-M0183
CDX-M0183
Regulatory Status:
RUO
RUO
Shipping:
AMBIENT
AMBIENT
Storage:
Short term: +4°C. Long term: +4°C
Short term: +4°C. Long term: +4°C
No additional charges, what you see is what you pay! *
Code | Size | Price |
---|
CDX-M0183-M050 | 50 mg | £68.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
Compactin; 6-Demethylmevinolin; CS-500; ML-236B; L-637,312; NSC 281245; Statin I
Appearance:
White to light yellow powder.
CAS:
73573-88-3
EClass:
32160000
Form (Short):
solid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
InChiKey:
AJLFOPYRIVGYMJ-INTXDZFKSA-N
Long Description:
Chemical. CAS: 73573-88-3. Formula: C23H34O5. MW: 390.51. Mevastatin is an antibiotic that is a competitive HMG-CoA reductase inhibitor, thus suppressing Ras farnesylation. Mevastatin decreases cholesterol biosynthesis in vitro and in vivo. It induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Mevastatin also suppresses TNF-induced NF-kappaB activation and potentiates apoptosis in human myeloid leukemia cells. Mevastatin induced neurite outgrowth of neuroblastoma cells via activation of EGFR, ERK1/2 and Akt/PBK but also exerts a neurotoxic effect in cultured neurons in a heme-independent manner. Mevastatin also shows antileishmanial and antifungal activity. Has also anti-inflammatory effects potentially via up-regulation of heme oxygenase-1 (HO-1).
MDL:
MFCD05662341
Molecular Formula:
C23H34O5
Molecular Weight:
390.51
Package Type:
Vial
Product Description:
Mevastatin is an antibiotic that is a competitive HMG-CoA reductase inhibitor, thus suppressing Ras farnesylation. Mevastatin decreases cholesterol biosynthesis in vitro and in vivo. It induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Mevastatin also suppresses TNF-induced NF-kappaB activation and potentiates apoptosis in human myeloid leukemia cells. Mevastatin induced neurite outgrowth of neuroblastoma cells via activation of EGFR, ERK1/2 and Akt/PBK but also exerts a neurotoxic effect in cultured neurons in a heme-independent manner. Mevastatin also shows antileishmanial and antifungal activity. Has also anti-inflammatory effects potentially via up-regulation of heme oxygenase-1 (HO-1).
Purity:
>95% (NMR)
SMILES:
[H][C@@]12C(C=C[C@H](C)[C@]2([H])CC[C@@]3([H])OC(C[C@@](O)([H])C3)=O)=CCC[C@@H]1OC([C@@H](C)CC)=O
Solubility Chemicals:
Soluble in DMSO or ethanol (20mg/ml). Insoluble in water.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
Documents
References
[1] A. Endo, et al.; FEBS Lett. 72, 323 (1976) | [2] R. Fears, et al.; Atherosclerosis 35, 439 (1980) | [3] K. Keyomarsi, et al.; Cancer Res. 51, 3602 (1991) | [4] A. Endo; J. Lipid Res. 33, 1569 (1992) | [5] S. Amin-Hanjani, et al; Stroke 32, 980 (2001) | [6] A. Wachtershauser, et al.; Carcinogenesis 22, 1061 (2001) | [7] K.S. Ahn, et al.; Biochem. Pharmacol. 75, 907 (2008) | [8] M.E. Evangelopoulos, et al.; J. Neurosci. Res. 87, 2138 (2009) | [9] M. Kannan, et al.; Neurobiol. Aging 31, 1543 (2010) | [10] N. Dinesh, et al.; Parasitol. Res. 114, 3873 (2015) | [11] S. Javed, et at.; Curr. Pharm. Biotechnol. 17, 291 (2016) | [12] Z. Lin, et al.; Oncotarget 8, 17833 (2017) | [13] C.-C. Lin, et al.; J. Clin. Med. 9, 226 (2020)